<DOC>
	<DOC>NCT00643643</DOC>
	<brief_summary>To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).</brief_summary>
	<brief_title>Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Inclusion criteria: Male with HIV or surgically sterilized female with HIV showing no symptoms of HIV Weight between 50 and 90kg and within the permitted range for their height Exclusion criteria: Subjects with a CD4 count less than 250cells/mm3 or HIV viral load of less than 5000 copies/mL Subjects with acquired immune deficiency syndrome (AIDS) or a previous AIDS diagnosis Subjects whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion Subjects who have taken antiretroviral drugs in the eight weeks prior to the study screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Na√Øve</keyword>
</DOC>